Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Guardant Launches Shield Test To Detect Colorectal Cancer In Average-Risk Adults

Executive Summary

The Shield lab-developed test was validated in a 309-patient study, demonstrating 91% sensitivity for colorectal cancer. The company is sponsoring the ECLIPSE study to support a PMA for the test.

You may also be interested in...



Report Digest: Tackling The Liquid Biopsy For Oncology Market With An Expert

In this first edition of Report Digest, UK-based reporter Barnaby Pickering discusses the liquid biopsy for oncology market with analyst Phil Greenfield. The two discuss the main market drivers and what experts think will occur in the sector in future years.

Guardant Reports Record Q3 Sales And A Buy Back From Softbank

Strong oncology sales have driven the company’s revenues to new heights, keeping it on target to meet its yearly revenue guidance.

Liquid Biopsy Company Adela Makes Debut With $60M In Series A Financing

Adela raised $60m to advance its DNA methylation technology for early cancer detection and disease monitoring.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT145352

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel